Article
Genomic alterations and dynamic molecular residual disease monitoring predict pathological response to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma.
Frontiers in immunology - 1 Jan 2026
Shen Dijian, Liang Jinxiao, Yan Junrong, Lu Weishan, Chen Da, Tao Kaiyi, Wang Mengyun, Chen Sheng, Chen Qixun
Abstract excerpt
Background: Approximately 40-60% of patients with locally advanced esophageal squamous cell carcinoma (ESCC) exhibit suboptimal responses to neoadjuvant chemoimmunotherapy (NCIT), highlighting the need for predictive biomarkers of pathological response. Methods: We prospectively enrolled 29 stage II-III ESCC patients receiving NCIT (albumin-paclitaxel/carboplatin + anti-PD-1). Baseline tumor tissues were firstly...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.